Vor Biopharma annual stock-based compensation
2020
2021
2022
2023
2024
2025
Vor Biopharma Stock-Based Compensation Growth & History (VOR)
Vor Biopharma's stock-based compensation was $18.9M for fiscal 2025.
View full Vor Biopharma company overviewVor Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.9M | $9.1M | +92.06% |
| 2024 | 2024-12-31 | $9.8M | −$3.5M | −26.31% |
| 2023 | 2023-12-31 | $13.4M | $2.7M | +24.94% |
| 2022 | 2022-12-31 | $10.7M | $6.4M | +147.86% |
| 2021 | 2021-12-31 | $4.3M | $3.0M | +221.54% |
| 2020 | 2020-12-31 | $1.3M | — | — |
Vor Biopharma quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.4M | $7.6M | +409.71% |
| Q1 2026 | 2026-03-31 | $8.9M | $6.9M | +358.87% |
| Q4 2025 | 2025-12-31 | $7.1M | $5.4M | +315.80% |
| Q3 2025 | 2025-09-30 | $8.0M | $5.8M | +254.64% |
| Q2 2025 | 2025-06-30 | $1.8M | −$949,000 | −33.98% |
| Q1 2025 | 2025-03-31 | $1.9M | −$1.1M | −37.26% |
| Q4 2024 | 2024-12-31 | $1.7M | −$185,000 | −9.77% |
| Q3 2024 | 2024-09-30 | $2.3M | −$898,000 | −28.40% |
| Q2 2024 | 2024-06-30 | $2.8M | −$1.4M | −34.10% |
| Q1 2024 | 2024-03-31 | $3.1M | −$987,000 | −24.26% |
| Q4 2023 | 2023-12-31 | $1.9M | −$2.0M | −51.17% |
| Q3 2023 | 2023-09-30 | $3.2M | −$167,000 | −5.02% |
| Q2 2023 | 2023-06-30 | $4.2M | $2.5M | +143.42% |
| Q1 2023 | 2023-03-31 | $4.1M | $2.3M | +132.99% |
| Q4 2022 | 2022-12-31 | $3.9M | $2.7M | +222.44% |
| Q3 2022 | 2022-09-30 | $3.3M | $2.2M | +188.47% |
| Q2 2022 | 2022-06-30 | $1.7M | $674,000 | +63.17% |
| Q1 2022 | 2022-03-31 | $1.7M | $855,000 | +95.96% |
| Q4 2021 | 2021-12-31 | $1.2M | $609,000 | +102.53% |
| Q3 2021 | 2021-09-30 | $1.2M | $671,000 | +138.92% |
| Q2 2021 | 2021-06-30 | $1.1M | $914,000 | +597.39% |
| Q1 2021 | 2021-03-31 | $891,000 | $779,000 | +695.54% |
| Q4 2020 | 2020-12-31 | $594,000 | — | — |
| Q3 2020 | 2020-09-30 | $483,000 | — | — |
| Q2 2020 | 2020-06-30 | $153,000 | — | — |
| Q1 2020 | 2020-03-31 | $112,000 | — | — |
Vor Biopharma stock-based compensation trends
Over the last five fiscal years, Vor Biopharma's stock-based compensation increased from $1.3M to $18.9M, a change of $17.6M. The latest reported quarter, Q2 2026, shows $9.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vor Biopharma source filings ↗